| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02613910 Details | 2017-06-14 Interventional | 3 | 1 | Acetaminophen Cetirizine Histamine Antag… Histamine H1 An… Ofatumumab Prednisolone Prednisone Pemphigus | Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059
studies. This decision is not linked to any safety consideration. - | |||
| NCT02439788 Details | 2017-06-14 Interventional | 1 | 0 | Cyclophosphamid… Fludarabine Neuroblastoma | Based on newly available preclinical data we changed the CAR construct to a more effective
version and will now study that product on a different protocol. - | |||
| NCT02352285 NCT01865214 Details | 2017-06-14 Interventional | 4 | 58 | Tolvaptan Heart Failure Hyponatremia Heart Failure W… | - - | |||
| NCT01760304 Details | 2017-06-14 Interventional | 4 | 5 | Budesonide Formoterol Fuma… Lung Diseases, … Pulmonary Disea… Chronic Obstruc… | Sponsor decided to stop the study due to expiration of blinded placebo . - | |||
| NCT01548573 Details | 2017-06-14 Interventional | 2 | 19 | Bortezomib Cyclophosphamid… Dexamethasone Doxorubicin Etoposide Etoposide phosp… Liposomal doxor… Melphalan Thalidomide Multiple Myelom… Neoplasms, Plas… | Met study stopping rules Enrollment halted prematurely. Study met stopping rules. Outcomes will not be tracked and published | |||
| NCT01381926 Details | 2017-06-14 Interventional | 4 | 14 | Exenatide Diabetes Mellit… Bone Remodeling Type 2 Diabetes… | unavailability of study drug and matching placebo Study was closed due to unavailability of study drug/matching placebo prior to recruitment of target participants. The original drug company was bought and new company was unwilling to supply medication. Small participant number limits data analysis. | |||
| NCT01173510 Details | 2017-06-14 Interventional | 4 | 0 | Efavirenz, Emtr… Emtricitabine, … Raltegravir Pot… Acquired Immuno… HIV Infections Immunologic Def… Acquired Immune… | This study was not feasible due to facility budget and contractual issues. - | |||
| NCT00934440 Details | 2017-06-14 Interventional | 1/2 | 11 | Azacitidine Bevacizumab Carcinoma Carcinoma, Rena… Renal Cell Carc… | - - | |||
| NCT00731692 NCT01779934 2007-002627-32 Details | 2017-06-14 Interventional | 3 | 970 | Fingolimod Hydr… Multiple Sclero… Multiple Sclero… Sclerosis Primary Progres… | The extension study was terminated early after the results of the core study showed the study
did not meet primary endpoint; confirmed disability progression - | |||
| NCT00719849 Details | 2017-06-14 Interventional | 2 | 13 | Antilymphocyte … Cyclophosphamid… Cyclosporine Cyclosporins Fludarabine Fludarabine pho… Mycophenolic Ac… Leukemia Lymphoma Multiple Myelom… Myelodysplastic… Myelodysplastic… Myeloproliferat… Neoplasms, Plas… Plasmacytoma Preleukemia Syndrome Multiple Myelom… Myelodysplastic… | A new protocol was developed to replace this protocol in 2008, with removal of ATG and
extension of MMF duration. - | |||
| NCT00662311 Details | 2017-06-14 Interventional | 1/2 | 5 | Paclitaxel Vorinostat Carcinoma, Non-… Lung Neoplasms Stage IIIA Non-… Stage IIIB Non-… | - - | |||
| NCT02194374 Details | 2017-06-12 Interventional | 1 | 0 | Bendamustine Hy… Cyclophosphamid… Fludarabine Fludarabine pho… Rituximab Leukemia Leukemia, Lymph… Leukemia, Lymph… | Study closed with no enrollment due to unavailability of reagent. - | |||
| NCT01725672 Details | 2017-06-12 Interventional | 1 | 20 | Glimepiride Metformin Diabetes Mellit… Diabetes Mellit… | Due to changes in EMA guidelines on modified release dosage forms (Feb 2013;
EMA/CHMP/EWP/280/96). The Part B formulation would not meet the new guidelines. - | |||
| NCT02969265 Details | 2017-06-09 Interventional | 3 | 0 | Amlodipine Candesartan Candesartan cil… Essential Hyper… Hypertension | Business reasons unrelated to product safety - | |||
| NCT02178813 Details | 2017-06-09 Interventional | 1 | 6 | Minocycline Stroke | Study stopped prematurely because of multiple logistic difficulties - | |||
| NCT01523548 Details | 2017-06-09 Interventional | 1/2 | 0 | Carbon Monoxide Hypertension Hypertension, P… Pulmonary Arter… | Lack of funding and subject acuity - | |||
| NCT01515046 Details | 2017-06-08 Interventional | 2 | 1 | Ascorbic Acid Gemcitabine Pancreatic Neop… Pancreatic Canc… | Standard of care changed to FOLFIRINOX; poor accrual. There was only one treated participant. Conclusions cannot be drawn from these data due to limited sampling size. | |||
| NCT01362608 2010-024172-26 Details | 2017-06-08 Interventional | 3 | 136 | Triamcinolone Triamcinolone A… Triamcinolone d… Triamcinolone h… Arthritis, Gout… Gouty Arthritis | - This study was terminated early. The decision to terminate study was not out of concerns for efficacy or safety of canakinumab | |||
| NCT00423150 Details | 2017-06-08 Interventional | 2 | [1 Refs] | 86 | Temozolomide Carcinoma, Non-… Colorectal Neop… Esophageal Neop… Head and Neck N… Neoplasms Colorectal Neop… Esophageal Neop… Head and Neck N… | - Due to low response rate for colorectal cancer in interim analyses, low enrollment in head & neck and non-small cell lung cancer groups due to low methylation rates, and low overall response rate in esophageal cancer group, the study was terminated. | ||
| NCT00005047 Details | 2017-06-08 Interventional | 3 | 521 | Doxorubicin Liposomal doxor… Methotrexate Vinblastine Urinary Bladder… Bladder Cancer | Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility
analysis. - |